Investigational ASOs for Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and transthyretin (TTR) amyloidosis, such as RG6042, tofersen and inotersen, respectively, are currently in phase III clinical trials. This evidence concerns the gene TTR and Huntington disease.